Speclipse Signs ODM Supply Agreement for Laser Products with InMode

Speclipse, a company specializing in skin treatment and skin cancer diagnostics, announced on September 1 that it has signed an Original Design Manufacturing (ODM) supply agreement for laser products with InMode Ltd. (CEO Moshe Mizrahy), a global leader in aesthetic medical devices.

InMode is the world’s top company in the sale of radio frequency (RF)-based minimally and non-invasive aesthetic medical devices. The company was listed on NASDAQ in 2019 and currently supplies products to 97 countries across the United States, Europe, Asia, and other regions.

Through this agreement, Speclipse will supply InMode with its specialized picosecond lasers and nanosecond lasers. The countries where these products will be sold include Germany and Austria, France and Belgium, the United Kingdom and Ireland, Italy, Spain and Portugal, Japan, Australia, and India. Supply will begin in the fourth quarter of this year.

This agreement was made possible after InMode, recognizing the strength of Speclipse’s laser technology, first proposed the collaboration. Speclipse, led by CEO Hong Junghwan, who began his career at the Korea Electrotechnology Research Institute, has been dedicated to the research and development of laser medical devices for over 20 years and continues to pursue innovative laser technology.

Based on this expertise, the company’s laser equipment delivers superior performance compared to competitors by generating stable picosecond and nanosecond pulses and maintaining a consistent laser beam size, which ensures uniform treatment effects without side effects.

Hong Junghwan, CEO of Speclipse, stated, "This contract with InMode, a world-renowned aesthetic medical device company, was made possible by Speclipse’s outstanding laser technology. We plan to obtain approval for our laser products from the U.S. Food and Drug Administration (FDA) and enter the U.S. market, the largest in the field of aesthetic medicine."

Byun Sunghyun, Chief Technology Officer (CTO) of Speclipse, said, "This agreement is the greatest achievement since the merger, combining Speclipse’s global network with KL’s technological capabilities. We will continue to create various achievements that expand the synergy from the merger."

Speclipse is aiming for a technology-based special listing in the second half of this year, with the goal of an initial public offering (IPO) next year. Korea Investment & Securities is serving as the lead underwriter.